An overview of best practice wound care in two cases of thromboangiitis obliterans.

J Vasc NursJul 7, 2026 (epub)
Case ReportVascular SurgeryGeneral Surgery

Semra Bulbuloglu, Gamze Oztoprak

✦ AI-curated · Sources linked

Case in brief

This report details two cases of thromboangiitis obliterans (TAO) leading to critical limb-threatening ischemia (CLTI) and subsequent wounds. Both patients had significant smoking histories. The first patient, a 47-year-old man, presented with foot pain and a wound, requiring debridement and moist wound care, but ultimately underwent toe amputation. The second patient, a 43-year-old man, developed wounds on his toes, leading to amputation of the fifth toe and hyperbaric oxygen therapy, with subsequent wound management following best practices.

Diagnostic / clinical pearl

Effective wound care in TAO patients includes irrigation, debridement, and promoting granulation, alongside smoking cessation to enhance healing outcomes.

Why it matters

This case underscores the importance of adhering to best practices in wound management for patients with TAO to improve limb salvage potential.

Source

PubMed · PMID 42637499

Published in J Vasc Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Vascular Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.